Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB Science AB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • English
  • French
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webconference replay
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Monthly Archives: July 2021

You are here:
  1. Home
  2. 2021
  3. July

Results from Phase 3 AB09004 study on Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)

2021By Alexis BERNARDJuly 29, 2021

29/07/2021 – AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the annual Alzheimer’s Association International Conference (AAIC)

Presentation of results from Phase 3 AB09004 study on Alzheimer’s disease at the annual Alzheimer’s Association International Conference (AAIC)

2021By Alexis BERNARDJuly 22, 2021

22/07/2021 – AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)

Publication in the world-renowned journal Science confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

2021By Alexis BERNARDJuly 20, 2021

20/07/2021 – AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern

Publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo

2021By Alexis BERNARDJuly 19, 2021

19/07/2021 – AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo

Validation of the Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France

2021By Alexis BERNARDJuly 12, 2021

12/07/2021 – AB Science announces the validation of its Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in France

Audio replay of the June 30 2021 Combined Shareholders’ Meeting

Uncategorised, UncategorizedBy adminJuly 1, 2021

Replay of the audio transcript in the audio player below: https://www.ab-science.com/wp-content/uploads/2021/07/2021-07-01_AG_AB_Science_du_30_Juin_2021.mp3

Results of the Combined General Shareholders’ Meeting of June 30, 2021

2021By Alexis BERNARDJuly 1, 2021

01/07/2021 – AB Science announces today the results of the Combined General Shareholders’ Meeting of June 30, 2021

AB Science
© AB Science – All right reserved
Go to Top